17.07.2024 12:27:48
|
Johnson & Johnson Q2 Profit Decreases, But Beats Estimates
(RTTNews) - Johnson & Johnson (JNJ) released earnings for second quarter that decreased from last year but beat the Street estimates.
The company's bottom line came in at $4.69 billion, or $1.93 per share. This compares with $5.38 billion, or $2.05 per share, in last year's second quarter.
Excluding items, Johnson & Johnson reported adjusted earnings of $6.84 billion or $2.82 per share for the period.
Analysts on average had expected the company to earn $2.70 per share, according to figures compiled by Thomson Reuters. Analysts' estimates typically exclude special items.
The company's revenue for the quarter rose 4.3% to $22.45 billion from $21.52 billion last year.
Johnson & Johnson earnings at a glance (GAAP) :
-Earnings (Q2): $4.69 Bln. vs. $5.38 Bln. last year. -EPS (Q2): $1.93 vs. $2.05 last year. -Revenue (Q2): $22.45 Bln vs. $21.52 Bln last year.
-Guidance: Full year EPS guidance: $9.97 - $10.07 Full year revenue guidance: $89.2 - $89.6 Bln

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Johnson & Johnsonmehr Nachrichten
21.02.25 |
Freitagshandel in New York: Dow Jones beendet den Handel in der Verlustzone (finanzen.at) | |
21.02.25 |
NYSE-Handel Dow Jones in der Verlustzone (finanzen.at) | |
21.02.25 |
Schwacher Handel in New York: Dow Jones mit Abgaben (finanzen.at) | |
20.02.25 |
Dow Jones aktuell: Dow Jones fällt letztendlich (finanzen.at) | |
20.02.25 |
Anleger in New York halten sich zurück: Dow Jones verliert (finanzen.at) | |
20.02.25 |
Dow Jones-Handel aktuell: Dow Jones notiert im Minus (finanzen.at) | |
19.02.25 |
Pluszeichen in New York: Dow Jones letztendlich mit positivem Vorzeichen (finanzen.at) | |
19.02.25 |
Handel in New York: Dow Jones gibt nach (finanzen.at) |
Analysen zu Johnson & Johnsonmehr Analysen
Aktien in diesem Artikel
Johnson & Johnson | 157,62 | 0,81% |
|